StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
TD Cowen on United Therapeutics Corp. (UTHR) Buyback: 'We believe that this signals management's confidence'
March 9, 2026 10:26 AM
TD Cowen analyst Joseph Thome reiterated a Buy rating and $575.00 price target on United Therapeutics Corp. (NASDAQ: UTHR).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments